Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018
JAMA — Fu M, Naci H, Booth CM, et al. | December 08, 2021
Over the past decade, a substantial increase in the estimated use of new cancer drugs without documented clinical benefit has been noted, with major cost implications.
This cross-sectional study was conducted to evaluate the use of and spending on new oral targeted cancer drugs in US residents with employer-sponsored insurance between 2011 and 2018, stratified by the strength of available evidence of benefit.
Participants were 37,348 patients who received 1 or more of 44 new oral targeted cancer drugs.
An increase from 13% in 2011 to 59% in 2018 was evident in the proportion of patients receiving drugs without documented overall survival benefit; accounting for 52% of the $3.5 billion estimated cumulative spending on the new oral targeted cancer drugs by the end of 2018.
Overall, cancer drugs without documented overall survival advantages are adopted in the health system and account for substantial spending.
Read the full article on JAMA